Apligraf® health economic analyses.

Apligraf has been proven to reduce the economic burden VLUs and DFUs have on patients and healthcare costs.1-6

The economic burden of treating unhealed VLUs and DFUs

Unhealed VLUs dramatically increase the economic burden on the healthcare system.1

78%

more hospital days

60%

more days of
home health

50%

more emergency
department visits

$14.9 billion

per year in
direct costs

Up to 27%

more outpatient visits

DFUs and their complications are a significant burden on the healthcare system.

47%

is the 5-year mortality rate in people with a diabetes-related amputation2

$17 billion per year

is the estimated associated cost to treat DFUs and DFU complications, including amputations3

Amputations

and their resulting extended hospital visits are one of the leading causes of higher costs in DFU cases4

Apligraf is proven to be cost-effective in treating VLUs and DFUs

An economic model estimated the annual medical cost and economic impact of managing patients with hard-to-heal VLUs.5

For patients treated with Apligraf, as compared with Unna's boot, patients had:

Approximately

$7500 less

in annual medical cost

Approximately

3 more months

in the healed state

Improved healing requiring

fewer months of treatment,

resulting in

lower overall treatment costs

In an analysis of Medicare claims for patients with DFUs, 502 Apligraf-treated patients were compared with their 502 conventional care counterparts.6

During the 18-month follow-up period, Apligraf patients had:

28%

reduction in lower
limb amputations

33%

fewer days
hospitalized

32%

fewer emergency
department visits

$5253

reduction in average
per-patient
healthcare costs

Support for you and your practice

See how Organogenesis' Circle of Care can help with reimbursement support and more, or contact an Organogenesis Tissue Regeneration Specialist to see how Apligraf can help your practice.

Contact us

REFERENCES:

  1. Rice JB, et al. J Med Econ. 2014;17(5):347-356.
  2. Moulik PK, et al. Diabetes Care. 2003;26(2):491-494.
  3. Barshes NR, et al. Diabet Foot Ankle. 2013;4. doi:10.3402/dfa.v4i0.21847
  4. Kirsner RS. Am J Manag Care. 2018;24(14, special issue):SP607-SP608.
  5. Schonfeld WH, et al. Wound Repair Regen. 2000;8:251-257.
  6. Rice JB, et al. J Med Econ. 2015;18(8):586-595.